NAT2 slow acetylation and bladder cancer in workers exposed to benzidine.
Authors
Carreón T; Ruder AM; Schulte PA; Hayes RB; Rothman N; LeMasters GK; Waters M; Grant DJ; Boissy R; Bell DA; Kadlubar FF; Hemstreet GP; Yin S; Li G; Feng P
Source
Proceedings of the 93rd American Association for Cancer Research Annual Meeting, April 6-10, 2002, San Francisco, California. Philadelphia, PA: American Association for Cancer Research, 2002 Apr; 43:938
The slow NAT2 N-acetylation genotype inhibits detoxification of a range of monoarylamines and has been associated with increased risk for bladder cancer in cigarette smokers and workers in arylamine dye production. The diarylamine, benzidine, is also a strong bladder carcinogen, however, NAT2 N-acetylation is not key to its detoxification. The purpose of this study was to expand on a previous study that evaluated the impact of NAT2 polymorphisms on bladder cancer in male subjects exposed only to benzidine. The combined analysis included 68 cases and 107 controls from a cohort of benzidine dye producers in China exposed occupationally to benzidine, of which 30 cases and 67 controls had not been previously studied. NAT2 enzymatic activity phenotype was characterized by measuring urinary caffeine metabolite ratios. Polymerase chain reaction (PCR)-based methods were used to identify genotypes for the NAT2 gene. A protective association was observed for the slow NAT2 genotype (bladder cancer odds ratio (OR)=0.3, 95% confidence interval (CI) 0.11-0.99) after adjustment for cumulative benzidine exposure and lifetime smoking. The interaction between NAT2 polymorphism and benzidine exposure was evaluated: compared to rapid acetylators with high exposure, the respective risks were OR=0.5 (95% CI 0.26-1.05) for rapid acetylators with low exposure, OR=0.4 (95% CI 0.12-1.57) for slow acetylators with high exposure, and OR=0.1 (95% CI 0.03-0.61) for slow acetylators with low exposure (test for multiplicative interaction, p=0.58). NAT2 phenotype results were consistent with NAT2 genotype data. Study findings confirm that slow acetylators are not at increased risk of developing benzidine-induced bladder cancer, in contrast to slow acetylators who smoke cigarettes or are exposed to monoarylamine dyes. The data actually suggest decreased risk for bladder cancer among NAT2 slow acetylators, although the mechanism for risk reduction is not clearly understood.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.